Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
N Eissler, R Altena, A Alhuseinalkhudhur, O Bragina… - Biomedicines, 2024 - mdpi.com
Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-Low breast Cancer with [68Ga] Ga-ABY-025: results from a pilot study
R Altena, S af Burén, A Blomgren… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Patients with HER2-low metastatic breast cancer (mBC), defined as an
immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit …
immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit …
Prediction of response to 177Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET/CT and posttherapeutic tumor-dose evaluation in …
M Hohberg, M Reifegerst, A Drzezga… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The aim of this study was to analyze the absorbed dose of 177Lu-PSMA in osseous versus
lymphatic metastases in patients with metastatic castration-resistant prostate cancer across …
lymphatic metastases in patients with metastatic castration-resistant prostate cancer across …
Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer
E Jussing, M Ferrat, MM Moein, H Alfredéen… - EJNMMI …, 2023 - Springer
Abstract Background The Affibody molecule, ABY-025, has demonstrated utility to detect
human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium …
human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium …
Theranostics-enabling high-tech centers: the value of centralizing resources in countries in development
P Kahlem, P Berenger-Molins, H Akbulut - F1000Research, 2024 - f1000research.com
Theranostics is a rapidly advancing field that is driving significant advancements in the
healthcare industry by providing individualized medical solutions. Demand for theranostics …
healthcare industry by providing individualized medical solutions. Demand for theranostics …
Recent Advances and Future Perspectives in Radiolabeled Antibody Fragments for Breast Cancer Molecular Imaging
R Gerami, MA Altafi, Z Shahpar, E Izadpanah… - Frontiers in Biomedical …, 2023 - fbt.tums.ac.ir
Breast Cancer (BC) is the leading cause of cancer-related deaths in women and the most
common cancer worldwide. It is classified based on its anatomical origin, the presence of …
common cancer worldwide. It is classified based on its anatomical origin, the presence of …
[引用][C] Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET
RD Seban - Journal of Nuclear Medicine, 2023 - Soc Nuclear Med
The results from the DESTINY-Breast04 trial, receiving a standing ovation during the
presidential symposium at the annual conference of the American Society of Clinical …
presidential symposium at the annual conference of the American Society of Clinical …